A Rare Pathology For Sudden Death İn a Raynaud Phenomenon: Resistant Coronary Vasospazm

Yıl 2020, Cilt: 15 Sayı: 2, 80 - 82, 08.07.2020

Sefa Tatar Sümeyye Fatma Özer Ahmet Soylu Ahmet Seyfeddin Gürbüz Yakup Alsancak Alpay Arıbaş Mükremin Coşkun Abdullah Özçelik

https://doi.org/10.17517/ksutfd.582155

Öz

Vasospastic angina is a type of angina pectoris, usually associated with transient ST-segment elevation, usually spontaneously or with nitrates. Sometimes we present with chest pain clinic, sometimes with more severe pictures and cardiac arrest. The impact of environmental factors on the triggering of the disease should not be ignored. In most patients, symptoms can be controlled by medical treatment. The main backbone of medical treatment is calcium channel blockers and vasodilator drugs.  In this article, we aimed to describe our patient with a resistant coronary osteal spasm.

Anahtar Kelimeler

Vasospastic angina, myocardial infarction, ventricular fibrillation, raynaud phenomenon

Kaynakça

• 1- Özyüncü N, Göksülük H, Vurgun VK, Yıldırım O, Tan Kürklü TS. Stent and implantable cardioverter defibrillator implantation in medically resistant vasospastic angina patient. Türk Kardiyol Dern Ars. 2017; 45(7): 641-645.
• 2- Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation 2011; 124: 1774–82.
• 3- JCS joint working group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2013). Circ J 2014; 78: 2779–801.
• 4- Ünalır A, Görenek B. Prinzmetal angina pektoris; patofizyolojik, klinik özellikler ve tedavide yeni yaklaşımlar. Türk Kardiyol Dem Arş 2000; 28: 314-320 .
• 5- Takagi Y, Takahashi J, Yasuda S, Miyata S, Tsunoda R, Ogata Y, Seki A, et al. Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol 2013; 62: 1144–53.
• 6- Fuertes J, Gallego P, Peinado R, Merino JL. Implantable cardioverter defbrillator as therapeutic option for sudden cardiac death secondary to severe coronary vasospasm. Int J Cardiol 1998; 63: 181–3.
• 7- Matsue Y, Suzuki M, Nishizaki M, Hojo R, Hashimoto Y, Sakurada H. Clinical implications of animplantable cardioverter-defibrillator in patients with vasospastic angina and lethal ventricular arrhythmia. J Am Coll Cardiol 2012; 60: 908–13.